Envestnet Portfolio Solutions Inc. Grows Position in Qiagen N.V. $QGEN

Envestnet Portfolio Solutions Inc. boosted its stake in shares of Qiagen N.V. (NYSE:QGEN) by 10.1% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 7,078 shares of the company’s stock after acquiring an additional 652 shares during the quarter. Envestnet Portfolio Solutions Inc.’s holdings in Qiagen were worth $340,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Yousif Capital Management LLC lifted its position in Qiagen by 3.7% during the 2nd quarter. Yousif Capital Management LLC now owns 6,257 shares of the company’s stock worth $301,000 after acquiring an additional 222 shares during the period. Truist Financial Corp lifted its position in Qiagen by 7.7% during the 2nd quarter. Truist Financial Corp now owns 6,170 shares of the company’s stock worth $297,000 after acquiring an additional 439 shares during the period. Johnson Investment Counsel Inc. lifted its position in Qiagen by 0.9% during the 2nd quarter. Johnson Investment Counsel Inc. now owns 57,119 shares of the company’s stock worth $2,745,000 after acquiring an additional 519 shares during the period. SVB Wealth LLC acquired a new stake in Qiagen during the 1st quarter worth approximately $31,000. Finally, Signaturefd LLC lifted its position in Qiagen by 23.2% during the 2nd quarter. Signaturefd LLC now owns 4,132 shares of the company’s stock worth $199,000 after acquiring an additional 778 shares during the period. 70.00% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms have weighed in on QGEN. Wall Street Zen cut Qiagen from a “buy” rating to a “hold” rating in a research report on Saturday, October 11th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Qiagen in a research report on Wednesday, October 8th. Bank of America raised their price target on Qiagen from $50.00 to $53.00 and gave the company a “buy” rating in a report on Thursday, June 26th. Cowen reissued a “hold” rating on shares of Qiagen in a report on Thursday, August 7th. Finally, Barclays set a $53.00 price target on Qiagen and gave the company an “overweight” rating in a report on Thursday, October 2nd. Three investment analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $49.69.

Qiagen Stock Performance

Shares of QGEN stock opened at $49.39 on Friday. The stock has a fifty day moving average price of $47.00 and a 200 day moving average price of $46.02. The stock has a market cap of $10.98 billion, a PE ratio of 29.18, a P/E/G ratio of 2.55 and a beta of 0.66. Qiagen N.V. has a 1 year low of $37.63 and a 1 year high of $51.88. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.35 and a current ratio of 1.61.

Qiagen (NYSE:QGEN) last issued its quarterly earnings data on Tuesday, August 5th. The company reported $0.60 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.60. The firm had revenue of $533.54 million during the quarter, compared to analysts’ expectations of $523.97 million. Qiagen had a return on equity of 14.77% and a net margin of 18.30%.Qiagen’s revenue was up 7.7% on a year-over-year basis. During the same period in the previous year, the firm posted $0.55 earnings per share. Qiagen has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. Sell-side analysts forecast that Qiagen N.V. will post 2.26 earnings per share for the current fiscal year.

Qiagen Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.